Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by C2N Diagnostics, LLC

News headline image
‘Live Long and Prosper’: Nimoy-Knight Foundation Selects C2N’s CEO and Co-Founder for Prestigious Award Following Alzheimer’s Disease Blood Test FDA Clearance
From C2N Diagnostics, LLC
Via Business Wire
News headline image
FDA Clears C2N Diagnostics’ PrecivityAD2® — First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40
From C2N Diagnostics, LLC
Via Business Wire
News headline image
United Kingdom Researchers Integrate C2N’s PrecivityAD2® Blood Test Into the Alzheimer’s Disease Diagnostic Care Pathway
From C2N Diagnostics, LLC
Via Business Wire
News headline image
Anthem Establishes Coverage of C2N Diagnostics’ PrecivityAD2® Blood Test for Alzheimer's Disease Evaluation
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics and SouthGenetics Partner to Enable Broader Access to Precivity® Blood Tests for Alzheimer’s Disease Assessment in Latin America, Caribbean
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics Highlights First Use of Its eMTBR-tau243 Plasma Assay in Evoke/Evoke+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests to Help Doctors Diagnose Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics Awarded Rigorous New York State Department of Health Permit, Expanding Ability to Provide Its Blood Tests to Help Diagnose Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Submits U.S. FDA Regulatory Filing for Its Alzheimer’s Disease Blood Test
From C2N Diagnostics, LLC
Via Business Wire
News headline image
New Research Reinforces C2N’s PrecivityAD2™ Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients
From C2N Diagnostics, LLC
Via Business Wire
News headline image
Dynamic Growth Leads C2N Diagnostics to Expand St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Announces Major Global Expansion, Adds Six New International Partners
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer’s Disease and Related Dementias
From C2N Diagnostics, LLC
Via Business Wire
News headline image
Samsung Invests in C2N Diagnostics
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom
From C2N Diagnostics, LLC
Via Business Wire
News headline image
Study Highlights How C2N’s PrecivityAD2™ Blood Biomarker Test Use Improves Clinical Decision-Making in the Evaluation for Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
News headline image
First Canadian Clinic to Offer C2N’s PrecivityAD2™ Blood Test to Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing Breakthrough Technology
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics Partners with The Michael J. Fox Foundation to Uncover New Links Between Parkinson’s Disease, Lewy Body Dementia and Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics and Unilabs Announce Global Partnership, Bringing Together Innovation Leaders in Diagnostics and Laboratory Medicine to Advance Brain Health
From C2N Diagnostics, LLC
Via Business Wire
News headline image
JAMA Publishes Landmark Clinical Study Showing C2N Diagnostics’ PrecivityAD2™ Blood Test Markedly Improves Accuracy of AD Diagnosis in Both Primary Care and Specialized Memory Care
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C₂N Diagnostics, LLC Announces Investment From Eisai Inc.
From C2N Diagnostics, LLC
Via Business Wire
News headline image
Researchers Identify New Cost Savings and Accuracy of C2N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease
From C2N Diagnostics, LLC
Via Business Wire
News headline image
New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease
From C2N Diagnostics, LLC
Via Business Wire
News headline image
C2N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology
From C2N Diagnostics, LLC
Via Business Wire
News headline image
On World Alzheimer’s Day, C2N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach
From C2N Diagnostics, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.